Aclaris Therapeutics, Inc. (LON:0H8T)
1.468
-0.022 (-1.48%)
At close: Jul 3, 2025
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.46M USD in the quarter ending March 31, 2025, a decrease of -39.32%. This brings the company's revenue in the last twelve months to $17.78M, down -42.87% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm)
$17.78M
Revenue Growth
-42.87%
P/S Ratio
8.30
Revenue / Employee
$277.77K
Employees
64
Market Cap
114.18M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Aclaris Therapeutics News
- 5 days ago - Aclaris Therapeutics joins Russell 3000 and Russell 2000 Indexes - Seeking Alpha
- 5 days ago - Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 9 days ago - Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - GlobeNewsWire
- 12 days ago - Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics GAAP EPS of -$0.12, revenue of $1.46M - Seeking Alpha
- 2 months ago - Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire